• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Thiel Foundation funds six visionary teams in innovation program

Thiel Foundation funds six visionary teams in innovation program

April 18, 2012
CenterWatch Staff

The Thiel Foundation has awarded its first six Breakout Labs grants, the company’s revolutionary revolving fund to promote innovation in science and technology.

Launched in November 2011, Breakout Labs provides teams of researchers in very early-stage companies with the means to pursue their most radical goals in science and technology. Breakout Labs has awarded six grants, of up to $350,000 each, to the following recipients:

3Scan plans to develop 3-D digital reconstruction of brain tissue, using a novel, faster, less expensive microscope technology. Building a map of connections in the brain—the connectome—is a critical step to understanding what makes the human brain unique.

Arigos Biomedical wants to develop methods of cooling organs for long-term storage. When combined with emerging advances in cryopreservation, tissue engineering and stem cell therapies to eliminate graft rejection, this technology would make banked organs immediately available to anyone needing a transplant.

Immusoft plans to re-program human immune cells to produce therapeutics in the body. This technology could dramatically improve the ability to treat a range of diseases, as well as enhance human health and longevity.

Inspirotec wants to develop a universal system for collecting and identifying virtually any airborne agent. Our environment is increasingly subject to natural and man-made toxins, and this technology would allow for their capture and identification in a simple, low-cost handheld device.

Longevity Biotech plans to develop an entirely new class of therapeutics via artificial protein technology (hybridtides). Hybridtides are targeted biologic-like molecules which are highly-resistant to breakdown by natural digestive enzymes and tunable to very stable molecular structures. These features have demonstrated potent therapeutic activity with the possibility of oral biologic delivery.

Positron Dynamics wants to enhance the production and collection of positrons, a class of elementary particles. Positrons have many near-term applications, for example, in medical imaging; in the long run, they may be a source of energy—antimatter propulsion—for space travel.

"In the past, people dreamed of the future as a radically better, more technologically advanced place: you might live for centuries, delegate work to your robots, and take your vacations on the moon," said Peter Thiel, who established and funds the Thiel Foundation. "Now, many people expect their children to inherit a world worse than today's. With Breakout Labs, we want to rekindle dreams of an amazing future. That's why we're supporting researchers who dream big and want to build a tomorrow in which we all want to live."

Most of the Breakout Labs grantees have only recently formed companies, conducting research in silico, in technology incubators, with academic collaborators and through CROs.

Breakout Labs accepts applications on a rolling basis. Although the program is open to proposals in any field of advanced science and technology, the current emphasis is on the intersection of biology and technology. Going forward, individual grants will be awarded as proposals emerge from the Breakout Labs' review process.

"We are thrilled with the quality of the applications we have received," said Breakout Labs' executive director, Lindy Fishburne. "The initial response to our program has signaled to us that we are addressing a critical gap in the support of early-stage science and technology taking place outside the traditional boundaries of universities and institutions. We look forward to receiving and funding more great proposals throughout the year."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing